30 closest matches · ranked by relevance
Polypharmacy
Primary: Number of Participants With Changes in Signs and Symptoms Related to Adverse Effects of Prescribed Medicines. Clinical Gains and Benefits to Residents — 17 Participants
Breast Neoplasms
Primary: Number of Participants With Factors Considered to Affect the Safety and/or Efficacy of Exemestane — 126; 324; 372; 68 participants
Seizures
Primary: Drug (Valproic Acid or Carbamazepine) Metabolite Profiles in Urine — 15.2; 13.1; 1.15; 2.13 nmol per mg creatinine
Rheumatoid Arthritis
Primary: Total Number of Patients With Adverse Events — 27.8 Percentage of Patients
Healthy Volunteers
Primary: Maximum Level of Sedation for Lorazepam 1 mg IM + ADASUVE 10 mg — 12.3 units on a scale
Overactive Bladder
Primary: Confirmation of the Incidence of All Treatment Related Adverse Events (TRAEs). — 984 participants
HIV-1 Infection
Primary: Number of Participants Who Reported Unlisted Adverse Drug Reaction. — 0 participants
Kidney Failure, Acute
Primary: Adverse Drug Events or Potential Adverse Drug Events — 99; 104 Patient-Medication Pairs
Acute Pain · Dysmenorrhea
Primary: Percentage of Patients With an Incidence of Adverse Event (AE) Associated to Potential Liver Damage During the Clinical Evaluation of Patients — 0.0 Percentage of Patients
Medication Adherence · Mobile Application
Primary: Usability of the SAM App — 1.14; 1.32; 1.35; 1.81 score on a scale
Smoking Cessation
Primary: Risk Factors for the Frequency of Treatment Related Adverse Events - Gender. — 377; 336 participants — p=<0.001
Acute Kidney Injury
Primary: Percentage of Patients With Progression of AKI OR Dialysis OR Death — 639; 585 Participants
Adverse Drug Events
Primary: Health Services Utilization 3 Months Following Hospital Discharge — 3.33; 3.40 Health Services Utilizations — p=.87
Panic Disorder · Depression
Primary: Number of Participants of Treatment Related Adverse Events (TRAEs) — 263 participants
Epilepsies, Partial
Primary: Number of Participants With Treatment-Related Adverse Events Unexpected From Japanese Package Insert — 27 participants
Alzheimer Disease
Primary: Time to Dispensing of Inappropriate Medication Prescription — 76.7; 77.9; 77.5 Percentage of Cumulative Incidence — p=0.76
Non-tuberculous Mycobacterial Diseases · Tuberculosis · Inhibition of Disseminated Mycobacterium Avium Complex Disease Associated With HIV Infections
Primary: Number of Patients With Adverse Drug Reactions in This Surveillance — 16; 7 Participants
Heart Disease
Primary: Number of Patients With Atrial Arrhythmia — 121; 134 Participants — p=0.34
Non-small Cell Lung Cancer
Primary: Number of Participants With Adverse Drug Reactions — 1858; 518 Participants
Drug Hypersensitivity
Primary: Skin Healing Time — 13.75; 19; 40.5; 34 days — p=0.01
Adverse Drug Interactions
Primary: Midazolam Clearance (Pharmacokinetic Measure of Cytochrome P450 3A4 Activity) — 604; 552; 541; 156 ng*min/ml
Pulmonary Hypertension
Primary: Number of Participants With Treatment-Related Adverse Events — 448; 101 Participants
Tuberculosis · Non-tuberculous Mycobacterial Diseases (Including MAC Disease)
Primary: Number of Participants With Treatment-Related Adverse Events — 387; 113 Participants
Acromegaly
Primary: Number of Participants With Treatment-Related Adverse Events — 89; 20 Participants
Drug Interactions
Primary: Difference in Clinically Significant Visual Analogue Scale for Pain and Nausea Change Between CYP2D6 Users and Non-users — 7.4; 10.9; -14.0 millimeters
Cognitive Deficits
Primary: Change From Baseline in COWA Unique Word Count — -0.407725385; -0.425898667; -0.412534118; -0.108298333 Word Count
CCR5-tropic HIV-1 Infection
Primary: Percentage of Participants With Adverse Drug Reactions (ADRs) — 23.53 percentage of participants
Gastrointestinal Stromal Tumors
Primary: Number of Participants With Treatment-Related Adverse Events — 450 Participants
Transthyretin Familial Amyloid Polyneuropathy
Primary: Percentage of Participants With ADRs in This Study — 58; 12 Participants
Adverse Drug Events
Primary: Time to Intervention Once an ADE Alert Has Fired in CPRS — 6.8; 8 hours to intervention — p=0.6680